CareLit Fachartikel

Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderate…

B. Siegmund, S. Danese, L. Peyrin-Biroulet, M. Dubinsky, P. Dulai, H. Tilg, S. Sloan, C. Rabbat, B. Sands, S. Vermeire · Zeitschrift für Gastroenterologie · 2024 · Heft 09 · S. e625-e626

Dokument
920477
CareLit-ID
Jahr
2024
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
B. Siegmund, S. Danese, L. Peyrin-Biroulet, M. Dubinsky, P. Dulai, H. Tilg, S. Sloan, C. Rabbat, B. Sands, S. Vermeire
Ausgabe
Heft 09 / 2024
Jahrgang 62
Seiten
e625-e626
Erschienen: 2024-09-01 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0044-1789726

Zusammenfassung

Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis

Schlagworte

Efficacy Safety De-Escalation Once-Daily Obefazimod Third Fifth Open-Label Maintenance Treatment Patients Moderately Zeitschrift für Gastroenterologie